戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ted in this issue employed the redesign of a minor histocompatibility antigen.
2 nd that the LIMS1 locus appeared to encode a minor histocompatibility antigen.
3 , a thirteen-residue, maternally transmitted minor histocompatibility antigen.
4 tinoic acid early transcript (Rae1) and H-60 minor histocompatibility antigen.
5 ing for major histocompatibility antigens or minor histocompatibility antigens.
6 yngeneic antigen-presenting cells presenting minor histocompatibility antigens.
7 ls in the development of humoral immunity to minor histocompatibility antigens.
8 ediated by donor T cells that recognize host minor histocompatibility antigens.
9 lografts that confront the host with foreign minor histocompatibility antigens.
10  were oligoclonal, pointing to a response to minor histocompatibility antigens.
11 yeloid-specific differentiation antigens and minor histocompatibility antigens.
12         The hypothesis that ICAM-1 acts as a minor histocompatibility antigen and that anti-ICAM-1 an
13 cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damag
14 the advances in systematic identification of minor histocompatibility antigens and neoantigens arisin
15 xpansion of Tregs against major and possibly minor histocompatibility antigens and predict the feasib
16 genes and subsequent reduced presentation of minor histocompatibility antigens and reduced ligation o
17 ansplant is acquired tolerance of allogeneic minor histocompatibility antigens and that posttransplan
18                          Immune responses to minor histocompatibility antigens are poorly understood
19 PK3 and the shared antigens do not represent minor histocompatibility antigens, as their sequences ar
20 an fluorescence intensity [aMFI] >= 1000), a minor histocompatibility antigen, associated with graft
21 r 2 (ARHGDIB) (adjusted MFI [aMFI]>=1000), a minor histocompatibility antigen, associated with graft
22  acute CD4+ T cell-mediated GVHD across this minor histocompatibility antigen barrier depends on the
23 f reproductive immunology, and how major and minor histocompatibility antigens, blood group antigens,
24 helper-deficient CD8(+) T-cell response to a minor histocompatibility antigen by phenotypic and in vi
25                                              Minor histocompatibility antigens contribute to the cont
26                     Here we describe a human minor histocompatibility antigen created by a polymorphi
27         On the other hand, the importance of minor histocompatibility antigens derived from nonhemato
28 ed this alloimmune syndrome in recipients of minor histocompatibility antigen disparate donor cells,
29                       When transplanted into minor histocompatibility antigen-disparate allogeneic re
30 row irradiation chimeras across the multiple minor histocompatibility antigen-disparate, C57BL/6-->BA
31 of cases across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-d cou
32  induced across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-day c
33 onor T cells that are specific for recipient minor histocompatibility antigens encoded by Y-chromosom
34                Allogeneic antibodies against minor histocompatibility antigens encoded on the Y chrom
35  to donor human leukocyte antigen molecules, minor histocompatibility antigens, endothelial cells, RB
36 duce ACAID, but soluble and cell-associated (minor histocompatibility) antigens generated cell-associ
37 etinoic acid early inducible (RAE-1) and H60 minor histocompatibility antigen genes on mouse chromoso
38 totoxic T cell clones specific for the human minor histocompatibility antigen H-Y and restricted by H
39 ignal peptide peptidase (SPP), also known as minor histocompatibility antigen H13.
40 ively mediated by T cells that recognize the minor histocompatibility antigen H60.
41 suggested that recipient mismatching for the minor histocompatibility antigen HA-1 is associated with
42                                          For minor histocompatibility antigens HA-1 and HA-2, normal
43 atched BALB.B spleen cells, despite multiple minor histocompatibility antigen (HA) differences.
44                     Indirect presentation of minor histocompatibility antigens (HA) as revealed by cr
45 ation produces HvG against the male specific minor histocompatibility antigen HY.
46 ed the HLA-B27-restricted CTL response to HY minor histocompatibility antigens in rats and mice trans
47 ors, including recognition of sex-determined minor histocompatibility antigens, influence of sex horm
48                                  In a single minor histocompatibility antigen (male to female)-depend
49       In addition, a better understanding of minor histocompatibility antigens may lead to more targe
50 of RBC products induced BMT rejection across minor histocompatibility antigen (mHA) barriers.
51 ined the immune response to DBY, a model H-Y minor histocompatibility antigen (mHA) in a male patient
52 C with grafts supplemented with T cells in a minor histocompatibility antigen (mHA)-mismatched mouse
53 rences in susceptibility to immune pressure, minor histocompatibility antigen (mHa)-specific T-cell l
54                                        Human minor histocompatibility antigens (mHA) and clinically r
55          Next, we immunized the donor to the minor histocompatibility antigens (mHA) of the recipient
56                                              Minor histocompatibility antigen (mHag) discordances hav
57 astocytoma in a murine model of MHC-matched, minor histocompatibility antigen (mHAg)-mismatched bone
58                                              Minor histocompatibility antigens (mHAg's) are peptides
59                                              Minor histocompatibility antigens (mHags) are immunogeni
60 le GVHD because of the presence of recipient minor histocompatibility antigens (mHAgs) in whole-cell
61 er of donor T cells that recognize recipient minor histocompatibility antigens (mHAgs) is a potential
62 he priming of donor T cells against putative minor histocompatibility antigens (mHAgs) on the tumor v
63                                              Minor histocompatibility antigens (mHAgs) present a sign
64                        T cell recognition of minor histocompatibility antigens (mHags) underlies allo
65                T cell alloreactivity against minor histocompatibility antigens (mHAgs)-polymorphic pe
66 herited major histocompatibility complex and minor histocompatibility antigens (mHAgs).
67 ced primarily by donor T-cell recognition of minor histocompatibility antigens (mHAgs).
68                                              Minor histocompatibility antigens (mHAs) are known targe
69      Alloreactive donor T cells against host minor histocompatibility antigens (mHAs) cause graft-ver
70              In contrast, the implication of minor histocompatibility antigens (mHAs) in AMR has not
71 le for increased rejection is likely against minor histocompatibility antigens (mHAs).
72 -encoded major HLA disparities or expressing minor histocompatibility antigen (miHA) differences pres
73 T(M) from donors vaccinated against a single minor histocompatibility antigen (miHA) expressed by leu
74 cient B6 (H-2(b)) recipients primed to donor minor histocompatibility antigen (MiHA) prior to BM tran
75                                              Minor histocompatibility antigen (miHA) vaccines have th
76 smatched, CD4-driven murine GVHD model and a minor histocompatibility antigen (MiHA)-mismatched, CD8-
77                                              Minor histocompatibility antigen (MiHA)-specific T cells
78 cing alloreactive T cell responses targeting minor histocompatibility antigens (MiHA) expressed on ma
79 mice and the interaction of these cells with minor histocompatibility antigen- (miHA-) mismatched CD8
80 SCT, CD8+ stem cell memory T cells targeting minor histocompatibility antigens (MiHAs) expressed by r
81 r magnitude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients wi
82 s) initiate GVHD by directly presenting host minor histocompatibility antigens (miHAs) to donor CD8 c
83 recognizing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are pres
84 including tumor-specific antigens (TSAs) and minor histocompatibility antigens (MiHAs).
85 onor and recipient were incompatible at many minor histocompatibility antigens (minor H Ags), the CD8
86                                              Minor histocompatibility antigens (minor H antigens) are
87 -dependent GVHD in a mouse model across only minor histocompatibility antigens (minor H antigens).
88 ned when Rux-chow was fed to C.B10 mice in a minor histocompatibility antigen mismatched (B6 C.B10) A
89                                           In minor histocompatibility-antigen mismatched allogeneic h
90  test the role of donor Stat1 in MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatc
91  study the mechanisms of DLI in MHC-matched, minor histocompatibility antigen-mismatched allogeneic c
92  histocompatibility complex-matched multiple minor histocompatibility antigen-mismatched alloHCT usin
93 usion may not apply to MHC-matched, multiple minor histocompatibility antigen-mismatched alloSCT, the
94                                    In both a minor histocompatibility antigen-mismatched as well as a
95                 Recipients were H-2-matched, minor histocompatibility antigen-mismatched C57BL/6 mice
96 ed, single Y chromosome-encoded, or multiple minor histocompatibility antigen-mismatched hematopoieti
97 r Histocompatibility Antigen Complex-matched minor Histocompatibility Antigen-mismatched murine model
98 platelets, and we report that transfusion of minor histocompatibility antigen-mismatched platelets in
99 play an important role in clinical GVHD in a minor histocompatibility antigen-mismatched setting.
100 major histocompatibility complex-matched and minor histocompatibility antigen-mismatched unrelated do
101 te infusions (DLIs) were incorporated into a minor histocompatibility antigen-mismatched, T cell-depl
102 ansplantation, donors' T cells can recognize minor histocompatibility antigens on recipient cells and
103 eved to be mediated by T-cell recognition of minor histocompatibility antigens on recipient cells.
104            The inclusion of SNPs that encode minor histocompatibility antigens or other genetic polym
105                                              Minor histocompatibility antigens play a significant rol
106           The GVL effect is directed against minor histocompatibility antigens shared by normal and l
107 ificantly suppressed the clonal expansion of minor histocompatibility antigen-specific CD8 T cells du
108 pleen cells do not inhibit allogeneic MHC or minor histocompatibility antigen-specific CTL production
109 bone marrow is not matched in the clinic for minor histocompatibility antigens, such as those carried
110 ying a murine model that uses differences in minor histocompatibility antigens to generate Scl GVHD.
111 grafts, skin differing from the host only by minor histocompatibility antigens undergoes slower (i.e.
112 matched donor MHC class I and II, and of H-Y minor histocompatibility antigen was assessed by quantif
113 kin and bone marrow, mismatched for multiple minor histocompatibility antigens, was induced in Fas mu
114 stent with a response to immunodominant host minor histocompatibility antigens, we detected oligoclon
115 for disparities in cytoplasmically inherited minor histocompatibility antigens, we examined one hyper
116 a strong genetic disparity in both major and minor histocompatibility antigens were used for transpla
117 cognition of these hematopoietically derived minor histocompatibility antigens will induce significan
118                                              Minor histocompatibility antigens with expression restri

 
Page Top